BR112015022146A2 - probiotic combinations to restore changes in bowel function - Google Patents

probiotic combinations to restore changes in bowel function

Info

Publication number
BR112015022146A2
BR112015022146A2 BR112015022146A BR112015022146A BR112015022146A2 BR 112015022146 A2 BR112015022146 A2 BR 112015022146A2 BR 112015022146 A BR112015022146 A BR 112015022146A BR 112015022146 A BR112015022146 A BR 112015022146A BR 112015022146 A2 BR112015022146 A2 BR 112015022146A2
Authority
BR
Brazil
Prior art keywords
effective amount
therapeutically effective
present
distinct
treatment
Prior art date
Application number
BR112015022146A
Other languages
Portuguese (pt)
Inventor
Alejandro Fiore Esteban
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of BR112015022146A2 publication Critical patent/BR112015022146A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo da patente de invenã§ã£o para: “combinaã‡ãƒo com probiã“ticos para restabelecer alteraã‡ã•es da funã‡ãƒo intestinalâ€�. a presente invenã§ã£o se refere a uma associaã§ã£o de probiã³ticos (pbts) com diferentes princã­pios ativos em monodoses, ou com outras associaã§ãµes fixas para restabelecer alteraã§ãµes da funã§ã£o intestinal. por conseguinte, a presente composiã§ã£o resulta ideal no tratamento dos distintos transtornos funcionais gastrointestinais e na sã­ndrome do intestino irritã¡vel (sii) ou cã³lon irritã¡vel (ci). como uma primeira modalidade, a presente invenã§ã£o se refere a uma composiã§ã£o farmaceuticamente oral, que se utiliza para restabelecer alteraã§ãµes da funã§ã£o intestinal, que compreende uma quantidade terapeuticamente eficaz de um principio ativo para o tratamento dos distintos transtornos funcionais gastrointestinais e uma quantidade terapeuticamente eficaz de um probiã³tico juntamente ã  excipientes farmaceuticamente aceitã¡veis e opcionalmente, uma quantidade terapeuticamente efetiva de pelo menos um nutracãªutico. uma modalidade adicional da presente invenã§ã£o se refere ao processo para preparar uma composiã§ã£o farmacãªutica oral que compreende granular, misturar e comprimir uma quantidade terapeuticamente eficaz do principio ativo para o tratamento dos distintos transtornos funcionais gastrointestinais e uma quantidade terapeuticamente eficaz de um probiã³tico juntamente ã  excipientes farmaceuticamente aceitã¡veis. em uma outra modalidade adicional, a presente invenã§ã£o descreve o uso de uma quantidade terapeuticamente eficaz de um principio ativo para o tratamento dos distintos transtornos funcionais gastrointestinais em combinaã§ã£o com uma quantidade terapeuticamente eficaz de um probiã³tico, para a fabricaã§ã£o de um medicamento para restabelecer funã§ãµes intestinais alteradas.Patent Summary for: "Combination with Problems to Reestablish Changes in Intestinal Function". The present invention relates to an association of probiotics (pbts) with different active principles in monodoses, or with other fixed associations to restore changes in intestinal function. therefore, the present composition is ideally suited for the treatment of distinct gastrointestinal functional disorders and irritable bowel syndrome (sii) or irritable bowel syndrome (ci). As a first embodiment, the present invention relates to a pharmaceutically oral composition which is used to restore changes in intestinal function comprising a therapeutically effective amount of an active ingredient. for the treatment of distinct gastrointestinal functional disorders and a therapeutically effective amount of a probiotic together with pharmaceutically acceptable excipients and optionally a therapeutically effective amount of at least one nutraceutical. A further embodiment of the present invention relates to the process for preparing an oral pharmaceutical composition comprising granulating, mixing and compressing a therapeutically effective amount of the active ingredient for the treatment of distinct gastrointestinal functional disorders and a therapeutically amount. of a probiotic together with pharmaceutically acceptable excipients. In another further embodiment, the present invention describes the use of a therapeutically effective amount of an active ingredient for the treatment of distinct gastrointestinal functional disorders in combination with a therapeutically effective amount of a probiotic for manufacture of a medicament for restoring altered intestinal functions.

BR112015022146A 2013-03-11 2014-03-11 probiotic combinations to restore changes in bowel function BR112015022146A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2013002737A MX2013002737A (en) 2013-03-11 2013-03-11 Combinations with probiotics for restoring alterations in intestinal function.
PCT/IB2014/059639 WO2014141075A1 (en) 2013-03-11 2014-03-11 Combinations with probiotics for restoring alterations in intestinal function

Publications (1)

Publication Number Publication Date
BR112015022146A2 true BR112015022146A2 (en) 2017-07-18

Family

ID=51535962

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022146A BR112015022146A2 (en) 2013-03-11 2014-03-11 probiotic combinations to restore changes in bowel function

Country Status (5)

Country Link
AR (1) AR095150A1 (en)
BR (1) BR112015022146A2 (en)
MX (1) MX2013002737A (en)
UY (1) UY35378A (en)
WO (1) WO2014141075A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018482A1 (en) * 2018-07-16 2020-01-23 Stc.Unm Treatment methods and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110679A1 (en) * 2011-04-20 2012-10-21 Giovanni Mogna COMPOSITION INCLUDING PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRICITY.
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes

Also Published As

Publication number Publication date
MX2013002737A (en) 2014-09-22
UY35378A (en) 2014-08-29
WO2014141075A1 (en) 2014-09-18
AR095150A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
BR112014018378A8 (en) CONTINUOUS PROCESS FOR THE PREPARATION OF A TABLET COMPRISING 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL5-IL)CYCLOPROPANOCARBOXAMIDO)-3-METHYLPYRIDIN-2-IL)BENZOIC ACID
BR112012024934A2 (en) pharmacologically induced transgene ablation systems
BR112015018168A2 (en) soft rock inhibitors
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
BR112015023922A2 (en) pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of using these
BRPI0919753B8 (en) polymorphic form of palmitoylethanolamide, pharmaceutical composition for human or veterinary use, method for micronization of palmitoylethanolamide and ultramicronized palmitoylethanolamide
BR112015006571A2 (en) pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition, and method for the prophylaxis or treatment of asthma, chronic obstructive pulmonary disease and related respiratory disorders
BR112015018087A8 (en) compound, pharmaceutical composition and use
BRPI0709847B8 (en) fast-release solid pharmaceutical composition containing acetaminophen and calcium carbonate
BR112018012870A2 (en) methods and compositions for the treatment of crisis-related disorders
BR112012016330B8 (en) ampk thieno[2,3-b]pyridinedione activators and pharmaceutical composition comprising the same
BRPI0922796A2 (en) PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION AND MANUFACTURING METHOD
BR112019001852A2 (en) cannabis composition
HN2011000864A (en) INHALABLE PARTICLES THAT INCLUDE TIOTROPIO
BR102013003570A8 (en) PLATELET-RICH PLASMA COMPOSITIONS
BRPI0510226A (en) solid pharmaceutical composition, solid dosage form, method for administering heparin to an animal, method for treating or preventing thrombosis in an animal, method for preparing a wet heparin solid dosage form
BR112012030641A2 (en) methods and compositions for oral pharmaceutical therapy
BRPI0915119B8 (en) use of carrageenan iota
BRPI0812432B8 (en) extrudates, their use, and medicine
BRPI0409742A (en) use of an anti-angiogenic agent, in combination with a src family inhibitor of non-receptor tyrosine kinases, combination product, and pharmaceutical composition
BR112015007360A2 (en) pharmaceutical composition and method for the preparation of a combination drug
CL2016001707A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (div. Sol. 1178-11).
EA201170108A1 (en) COSMETIC COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE ORAL CAVITY AND SIPS
BR112015022146A2 (en) probiotic combinations to restore changes in bowel function
BRPI0700133A (en) pharmaceutical composition comprising tramadol and ketoprofen in combination

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements